Summary of findings 2. Summary of findings table 2.
| Ivermectin versus thiabendazole for treating strongyloides infection | |||||
| Patient or population: patients with treating strongyloides infection Settings: worldwide Intervention: ivermectin versus thiabendazole | |||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of participants (trials) | Quality of the evidence (GRADE) | |
| Assumed risk | Corresponding risk | ||||
| Thiabendazole | Ivermectin | ||||
| Cure overall negative parasitological test Follow‐up: mean 11 weeks | 69 per 100 | 74 per 100 (66 to 82) | RR 1.07 (0.96 to 1.2) | 467 (3 trials) | ⊕⊕⊝⊝ low1 |
| Adverse events report of adverse events Follow‐up: mean 11 weeks | 73 per 100 | 23 per 100 (15 to 36) | RR 0.31 (0.2 to 0.5) | 507 (3 trials) | ⊕⊕⊕⊝ moderate1 |
| *The basis for the assumed risk (eg the median control group risk across trials) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: confidence interval; RR: risk ratio. | |||||
| GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. | |||||
1Downgraded by 1 for risk of bias: 2 trials did not conceal allocation, and no method of allocation is described in one trial.